We’re governed by a Board, which is advised by the Corporate Executive Team (CET).
The Board is responsible for advising on the strategic development of the agency and ensuring that targets set out in the business plan and agreed with ministers are met.
The Board does not have involvement in any regulatory decisions affecting medicines or medical devices. These are the responsibility of the Chief Executive (working through the CET), and of the expert advisory committees.
Full details of the Board’s responsibilities can be found in our
The Board is chaired by MHRA’s chairman, and consists of 8 non-executive directors (NEDs) and 2 executive members (the Chief Executive and Chief Operating Officer).
Stephen Lightfoot(chair), Deputy Chair of Sussex Community NHS Foundation Trust
Dr June Raine CBE, Chief Executive, MHRA
Mr Jon Fundrey ,Chief Operating Officer and Director of Finance, MHRA
Dr Barbara Bannister MBE, honorary consultant at the Royal Free Hospital and advisor on military medicine to the Ministry of Defence
Amanda Calvert, Non-Executive Director of The Guinness Partnership Limited a provider of social housing and care services and a member of the Advisory Board of the Cambridge Judge Business School
Professor Bruce Campbell, consultant vascular surgeon at the Royal Devon and Exeter Hospital and Honorary Professor at the University of Exeter Medical School
Mercy Jeyasingham MBE, management consultant specialising in managing charities, who has been working in the voluntary health and social care sector for over 30 years
Anne-Toni Rodgers, Pharmacologist and Director of a management consultancy
Professor Liam Smeeth, Professor of Clinical Epidemiology at the London School of Hygiene and Tropical Medicine
Professor David Webb, (Deputy Chair of the Board)
Christison Chair of Therapeutics and Clinical Pharmacology at the University of Edinburgh
Michael Whitehouse OBE, Accountant and auditor, and non-executive director with other bodies
Board members’ declarations of interest
Older minutes are available on the National Archives website.
MHRA Board Meetings in 2020
Our next MHRA Board Meeting held in public will be conducted virtually by webinar on:
- Monday 26 October 2020 from 10.30am until 1.00pm (GMT).
This meeting is now open for public registrations. Book your place.
Previous Board meetings and public sessions
Papers for Board meeting (public session) 16 September 2019
MHRA Board Meeting: April 2019
MHRA Board Meeting: October 2018
Members of the public and staff observers will have an opportunity to ask questions at the end of each item at the discretion of the Chair.
MHRA Board Meeting: 23 April 2018
MHRA Board Meeting: 15 December 2017
MHRA Board meeting: 20 October 2017
MHRA Board meeting: 24 April 2017
Corporate Executive Team (CET)
The Corporate Executive Team (CET) - previously the Executive Board - is the highest executive decision-making body of the Agency. The CET is chaired by the Interim Chief Executive, Dr June Raine, and is made up of:
- the directors of each of the MHRA’s divisions
- the director of the National Institute for Biological Standards and Control (NIBSC)
- the director of the Clinical Practice Research Database (CPRD)
- a representative from the Department of Health Legal Services
The CET has overall responsibility for:
- day-to-day management
- strategic decision-making
- line management
- all financial, policy, operational and resource management issues
Full details of the CET’s responsibilities can be found in our terms of reference.
Corporate Executive Team (CET) declarations of interest
Conflicts of interest between our 3 constituent groups
The work carried out by the MHRA, the National Institute for Biological Standards and Control (NIBSC) and the Clinical Practice Research Datalink (CPRD) is closely linked. Since our merger we know that some of the work NIBSC and CPRD do may need to be regulated by the MHRA. We know that this is a potential conflict of interest because of our close relationship. To help deal with these situations, we have produced a policy for handling conflicts of interest.